Kira-Lee Koster
Von-Hippel-Lindau-Erkrankung
Koster K, Rothermundt C, Binet F, Borovicka J, Bozinov O, Clerici T, Engeler D, Greiner J, Hader C, Heinimann K, Azzarello-Burri S, Lang C, Krull I, Stöckli S, Omlin A, Hundsberger T. Von-Hippel-Lindau-Erkrankung - Interdisziplinäre Betreuung und neue therapeutische Optionen. Swiss Med Forum 2022; 48:4-784-787.
30.11.2022Von-Hippel-Lindau-Erkrankung
30.11.2022Swiss Med Forum 2022; 48:4-784-787
Koster Kira-Lee, Rothermundt Christian, Binet Françoise-Isabelle, Borovicka Jan, Bozinov Oliver, Clerici Thomas, Engeler Daniel, Greiner J, Hader Claudia, Heinimann Karl, Azzarello-Burri Silvia, Lang Corina, Krull Ina, Stöckli Sandro, Omlin Aurelius, Hundsberger Thomas
Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.
Koster K, Appenzeller C, Lauber A, Früh M, Schmid S. Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases. Case Rep Oncol 2022; 15:720-725.
26.08.2022Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.
26.08.2022Case Rep Oncol 2022; 15:720-725
Koster Kira-Lee, Appenzeller Christina, Lauber Arno, Früh Martin, Schmid Sabine
New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development.
Koster K, Huober J, Jörger M. New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development. Explor Target Antitumor Ther 2022; 3:27-36.
24.02.2022New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development.
24.02.2022Explor Target Antitumor Ther 2022; 3:27-36
Koster Kira-Lee, Huober Jens, Jörger Markus